Lenalidomide plus rituximab to prevent brain lymphoma return
Part of Blood & lymphatic, Brain & nervous system, Cancer clinical trials.
This trial studies whether lenalidomide and rituximab can help keep primary CNS lymphoma from coming back after initial chemotherapy. It may be an option if you cannot do a transplant and you can take pills.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with primary CNS lymphoma in the brain/central nervous system, and the chemo worked (complete or partial response).
- You cannot get an autologous stem cell transplant (either due to age/weak health with high-dose chemo or you choose not to do it).
- You have blood counts and organ tests in safe ranges (enough white cells, platelets, hemoglobin, and acceptable kidney/liver levels).
- You can take oral (by mouth) medication and can follow study visits and consent requirements.
- You must be able to follow pregnancy prevention rules: not pregnant, with required pregnancy tests if able to become pregnant, and effective contraception during and after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies lenalidomide taken after your first treatment has worked for primary central nervous system lymphoma (PCNSL). It aims to help keep the lymphoma from coming back by testing lenalidomide as ongoing “maintenance” treatment.
This Phase 1 trial tests adding two cancer medicines—lenalidomide and nivolumab—to the usual treatment for primary CNS diffuse large B-cell lymphoma (a type of lymphoma in the brain/spinal fluid). The goal is to see if the combination is safe and if it works better than the usual approach.
This trial studies whether lenalidomide maintenance (ongoing pill treatment after remission) can help prevent relapse in people with primary central nervous system lymphoma or primary eye lymphoma. It’s aimed at adults who already completed standard chemo and radiation and are now in a complete or partial response.
This trial tests a combination of three drugs (poseltinib, rituximab, and lenalidomide) for people with primary central nervous system lymphoma that has come back or not responded to earlier treatment. The goal is to see if this new mix can help control the disease.
This trial tests a combination of two drugs, tafasitamab and lenalidomide, for people whose central nervous system lymphoma has come back. The goal is to see if this treatment can help shrink the cancer or slow its growth.
This Phase 2 study tests a combination treatment to shrink primary central nervous system lymphoma that starts in the brain, spinal cord, meninges, or eye. It may help patients who have not had anti-cancer treatment yet, but it requires specific cancer type and health conditions.
Hear when a new Primary CNS Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.